Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

Nettles RE, Kieffer TL, Kwon P, Monie D, Han Y, Parsons T, Cofrancesco J Jr, Gallant JE, Quinn TC, Jackson B, Flexner C, Carson K, Ray S, Persaud D, Siliciano RF.

JAMA. 2005 Feb 16;293(7):817-29.

PMID:
15713771
2.

HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.

Hermankova M, Ray SC, Ruff C, Powell-Davis M, Ingersoll R, D'Aquila RT, Quinn TC, Siliciano JD, Siliciano RF, Persaud D.

JAMA. 2001 Jul 11;286(2):196-207.

PMID:
11448283
3.
4.

HIV-1 viral load blips are of limited clinical significance.

Lee PK, Kieffer TL, Siliciano RF, Nettles RE.

J Antimicrob Chemother. 2006 May;57(5):803-5. Epub 2006 Mar 13.

PMID:
16533823
5.

Prevalence and predictive value of intermittent viremia with combination hiv therapy.

Havlir DV, Bassett R, Levitan D, Gilbert P, Tebas P, Collier AC, Hirsch MS, Ignacio C, Condra J, Günthard HF, Richman DD, Wong JK.

JAMA. 2001 Jul 11;286(2):171-9.

PMID:
11448280
6.

Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy.

Macias J, Palomares JC, Mira JA, Torres MJ, García-García JA, Rodríquez JM, Vergera S, Pineda JA.

J Infect. 2005 Oct;51(3):195-200. Epub 2005 Jan 12.

PMID:
16230215
7.
8.

Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy.

Di Mascio M, Ribeiro RM, Markowitz M, Ho DD, Perelson AS.

Math Biosci. 2004 Mar-Apr;188:47-62.

PMID:
14766093
9.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA.

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728
10.

Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance.

Cohen Stuart JW, Wensing AM, Kovacs C, Righart M, de Jong D, Kaye S, Schuurman R, Visser CJ, Boucher CA.

J Acquir Immune Defic Syndr. 2001 Oct 1;28(2):105-13.

PMID:
11588503
11.

Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels.

Sörstedt E, Nilsson S, Blaxhult A, Gisslén M, Flamholc L, Sönnerborg A, Yilmaz A.

BMC Infect Dis. 2016 Jun 21;16:305. doi: 10.1186/s12879-016-1628-6.

12.

Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals.

Zoufaly A, Kiepe JG, Hertling S, Hüfner A, Degen O, Feldt T, Schmiedel S, Kurowski M, van Lunzen J.

HIV Med. 2014 Sep;15(8):449-57. doi: 10.1111/hiv.12134. Epub 2014 Feb 24.

13.

Influence of treatment complexity on adherence and incidence of blips in HIV/HCV coinfected patients.

Calvo-Cidoncha E, González-Bueno J, Almeida-González CV, Morillo-Verdugo R.

J Manag Care Spec Pharm. 2015 Feb;21(2):153-7.

14.

Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure.

Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, Gregis G, Quinzan G, Soavi L, Iannotti N, Malfatto E, Leone S.

J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):473-82. doi: 10.1097/QAI.0b013e3182567a57.

PMID:
22481602
15.

Update on HIV-1 viral load blips.

Nettles RE, Kieffer TL.

Curr Opin HIV AIDS. 2006 Mar;1(2):157-61. doi: 10.1097/01.COH.0000203834.24221.13.

PMID:
19372801
16.

Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia.

Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ.

J Infect Dis. 2007 Dec 15;196(12):1773-8. doi: 10.1086/523704.

PMID:
18190257
17.

HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen.

Martinez V, Marcelin AG, Morini JP, Deleuze J, Krivine A, Gorin I, Yerly S, Perrin L, Peytavin G, Calvez V, Dupin N.

AIDS. 2005 Jul 1;19(10):1065-9.

PMID:
15958838
18.

Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy.

Nettles RE, Kieffer TL, Simmons RP, Cofrancesco J Jr, Moore RD, Gallant JE, Persaud D, Siliciano RF.

Clin Infect Dis. 2004 Oct 1;39(7):1030-7. Epub 2004 Sep 1.

PMID:
15472857
19.

Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, Peytavin G, Tubiana R, Pialoux G, Katlama C.

Clin Infect Dis. 2010 Mar 1;50(5):773-8. doi: 10.1086/650538.

PMID:
20100092
20.

Supplemental Content

Support Center